Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CNNM4 siRNA
- Development stage
- Preclinical
- Lead developer
- Gibela Therapeutics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
CNNM4 siRNA is a hepatocyte-targeted small interfering RNA (siRNA) therapeutic designed to silence the expression of Cyclin M4 (CNNM4), a magnesium exporter that is upregulated in various liver pathologies. Developed by Gibela Therapeutics (a spin-off from CIC bioGUNE) in collaboration with Silence Therapeutics using their proprietary mRNAi GOLD platform technology, the siRNA is conjugated to N-acetylgalactosamine (GalNAc) to enable specific delivery to hepatocytes via the asialoglycoprotein receptor (ASGPR). By silencing CNNM4, the therapy restores intracellular magnesium homeostasis, which in turn alleviates mitochondrial dysfunction, reduces endoplasmic reticulum (ER) stress, and mitigates liver injury. CNNM4 siRNA is currently in preclinical development for multiple liver-related conditions, including alpha-1 antitrypsin deficiency (AATD), metabolic dysfunction-associated steatotic liver disease (MASLD/MASH), cholangiocarcinoma (CCA), alcohol-related liver disease (ALD), drug-induced liver injury (DILI), and cholestatic liver disease.
- Other names
- Cnnm4 siRNACnnm-4 siRNACnnm 4 siRNAGalNAc siCnnm4GalNAc-siRNA CNNM4siRNA-Cnnm4siRNA-Cnnm-4siRNA-Cnnm 4
Beyond the preview
Go deeper on CNNM4 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CNNM4 siRNA.